[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intensity-modulated-radiation-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intensity-modulated-radiation-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100509108","omitting-clinical-target-volume-in-radical-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer-100509108",false,"NCT05909137","Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer","Feasibility of Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* •Patients with advanced (Stage IIIA or IIIB AJCC 7) NSCLC that was histologically or cytologically inoperable\n\n  * ECOG whole body status (performancestatus,PS) level 0 or 1\n  * The estimated survival time is more than 12 weeks, 18 \\~80 years old\n  * Laboratory results within 2 weeks prior to radiotherapy met the following criteria: ① Neutrophil count \\> 1,500\u002F MCL Heathko-Pilot Oncology Research Fund; ② Platelet \\> 50,000\u002F MCL; ③ Total bilirubin \\\u003C 1.5 times of the normal upper limit value; ④AST(SGOT)\u002FALT(SGPT) \\\u003C 2.5 times of the normal upper limit; ⑤ Serum creatinine \\\u003C 1.5 times of the normal upper limit value; ⑥ The results of coagulation function examination were within the normal range\n  * Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy tests (serum or urine) within 7 days before admission, and the results are negative, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug. For men, they must agree to use appropriate methods of contraception or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug\n  * Understand and voluntarily sign written informed consent\n  * The investigator judged that the patient had good compliance\n\nExclusion Criteria:\n\n* Malignant pleural\u002Fpericardial effusions, previous thoracic radiotherapy or chemotherapy\n* Uncontrolled concurrent diseases, including but not limited to symptomatic congestive heart failure, unstable angina pectoris and myocardial infarction, uncontrolled grade III hypertension, liver insufficiency, renal insufficiency, uncontrolled diabetic blood sugar, arrhythmia, mental illness or social condition, etc.\n* Pregnant or nursing women\n* The patient has no history of intracranial hemorrhage or spinal cord hemorrhage\n* HIV-positive patients receiving combination antiretroviral therapy\n* Active tuberculosis\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Prior allogeneic stem cell or solid organ transplantation\n* Researchers determine other conditions that may affect the conduct of clinical studies and the determination of their findings",true,"ALL","18 Years","80 Years",{"count":21,"type":22},60,"ESTIMATED","OBSERVATIONAL","Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC. Our preliminary study confirmed that the treatment of CTV-omitted IMRT regimen did not compromise the PFS or OS and significantly reduced the incidence of severe radiation pneumonia and radiation esophagitis.\n\nThe purpose of this study was to observe the role of radiotherapy modalities that omit CTV in the context of immunotherapy for NSCLC.",[26,27,28,29],"Immunotherapy","Intensity Modulated Radiation Therapy","Radiotherapy","NSCLC",[31,32,33],"IMRT","immunotherapy","CTV","NOT_YET_RECRUITING","2025-07-11",{"date":37,"type":38},"2025-07-14","ACTUAL",{"date":40,"type":22},"2026-02",{"date":42,"type":22},"2026-12",{"name":44,"class":45},"Xinqiao Hospital of Chongqing","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100579637","safety-and-efficacy-of-impt-or-imrt-for-breast-cancer-100579637","NCT06826885","Safety and Efficacy of IMPT or IMRT for Breast Cancer","The Safety and Efficacy of IMPT or IMRT for Breast Cancer: A Prospective Observational Study","SEPPT-BC","Inclusion Criteria\n\n* Aged ≥18 years old\n* Karnofsky Performance Status (KPS) score ≥70\n* Histologically confirmed breast cancer with indications for preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy as determined by the treating physician.\n* ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2), and Ki67 testing must be performed on the primary breast tumor.\n* Women of child-bearing potential must agree to use adequate contraception starting 1 month before study treatment and throughout the duration of study participation.\n* Ability to understand and willingness to participate in the research and sign the informed consent form.\n\nExclusion Criteria\n\n* Pregnant or lactating women.\n* Severe non-neoplastic medical comorbidities that may interfere with treatment or study participation.\n* Active collagen vascular disease or other autoimmune disorders that could significantly increase the risk of radiation toxicity.\n* Patients with contraindications to undergoing IMPT or IMRT, such as severe claustrophobia that cannot be managed or inability to remain immobilized during treatment.",{"count":55,"type":22},500,"5 Years","The purpose of this trial is to compare the toxicities and efficacy of intensity-modulated proton therapy (IMPT) and intensity-modulated radiation therapy (IMRT) for breast cancer patients indicated for radiotherapy including preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy. IMPT or IMRT will be administered to the whole breast, chest wall, and\u002For regional lymph nodes. A boost dose will be delivered in patients with high-risk area, at the discretion of the radiation oncologist. Eligible breast cancer patients will be followed for at least 5 years to assess acute and late radiation induced toxicities, loco-regional recurrence, overall survival, distant metastasis, and quality of life.",[59,60,27,61,62],"Breast Cancer","Proton Therapy","Efficacy and Safety","Radiotherapy, Adjuvant",[64,65,66,31,67,68,69],"postoperative radiotherapy","preoperative radiotherapy","IMPT","breast cancer","efficacy","toxicity","RECRUITING","2025-02-13",{"date":73,"type":38},"2025-02-14",{"date":75,"type":38},"2024-12-01",{"date":77,"type":22},"2029-11-30",{"name":79,"class":45},"Ruijin Hospital",1]